Strong Ph III data for GlaxoSmithKline/Impax Parkinson's drug

16 March 2011

UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday announced positive, top-line results of the ADVANCE-Parkinson’s Disease Phase III clinical study, conducted by US partner Impax Pharmaceuticals (Nasdaq: IPXL) of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations.

IPX066 is an investigational extended release (ER) CD-LD product which is being developed by Impax in collaboration with GSK in a deal that could earn the US firm up to $186 million, $11.5 million of which was up-front (The Pharma Letter December 17, 2010). Under the terms of the deal, Impax will develop and commercialize IPX066 in the USA and Taiwan, and GSK will develop and commercialize IPX066 in all other markets throughout the world. Impax will also receive tiered, double-digit royalty payments on GSK sales of IPX066, which the US firm will manufacture and supply to GSK.

US sales of $400 million forecast

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK